A California superior court judge has ruled that several Actos lawsuits filed in the state will be allowed to move forward in Los Angeles district court. The ruling is a victory for attorneys representing the Actos users involved in the lawsuits, who had fought efforts by Takeda Pharmaceuticals, the manufacturer of Actos, to move the cases to U.S. District Court in Louisiana.
Actos is a type-II diabetes drug that has been linked to an increased risk of bladder cancer. Concerns about the drug arose in September 2010, when a safety review conducted by the Food and Drug Administration found that Actos users were 40% more likely to develop bladder cancer than users of other diabetes drugs. In June 2011, the FDA issued a warning to doctors and patients about the link between Actos and bladder cancer.
The first Actos lawsuit was filed on behalf of a patient who developed bladder cancer in August 2011. Actos lawyers involved in similar cases have predicted that thousands of lawsuits may eventually be filed on behalf of patients who developed bladder cancer after taking the diabetes drug.